[1] Gofton C, Upendran Y, Zheng M H, et al. MAFLD:how is it different from NAFLD?[J]. Clin Mol Hepatol, 2023, 29(Suppl):S17-S31. [2] Gulati A, Roytman M, Lin J,et al. Association between Helicobacter pylori infection, MASLD, and liver fibrosis in patients with severe obesity:a single-center experience[J]. Surg Endosc, 2024, 38(11):6873-6879. [3] 卢俊如,侯凯文,王德英. LECT2、FGF21水平在T2DM伴NAFLD患者中的变化及其临床意义[J]. 医学分子生物学杂志, 2024, 21(3):270-274. [4] 李潇萌,吴少玉,王媛媛. 非酒精性脂肪性肝病合并2型糖尿病患者血清同型半胱氨酸、成纤维细胞生长因子21和核因子-κB水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2023, 26(2):202-205. [5] 中华医学会肝脏病学分会脂肪肝和酒精性肝病学组. 非酒精性脂肪性肝病诊疗指南[J]. 中华肝脏病杂志, 2006, 14(3):161-163. [6] 燕飞,吴春松,刘均艳,等. 幽门螺杆菌感染与非酒精性脂肪性肝病及糖脂代谢和血清炎症因子的关系[J]. 中华医院感染学杂志, 2024, 34(7):1007-1011. [7] Zhang D, Wang Q, Bai F. Bidirectional relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease:insights from a comprehensive meta-analysis[J]. Front Nutr, 2024, 11:1410543. [8] Mogna-Peláez P, Romo-Hualde A, Riezu-Boj J I,et al. Isoliquiritigenin in combination with visceral adipose tissue and related markers as a predictive tool for nonalcoholic fatty liver disease[J]. J Physiol Biochem, 2024, 80(3):639-653. [9] Tripathi M, Singh B K, Yen P M. Reply to:"Hyperhomocysteinemia predicts liver-related clinical outcomes in the general population"[J]. J Hepatol, 2023, 78(5):e174-e175. [10] Maiorana F, Neschuk M, Caronia M V, et al. Helicobacter pylori cagA/vacAs1-m1 strain is associated with high risk of fibrosis in metabolic-dysfunction-associated steatotic liver disease[J]. Ann Hepatol, 2024, 29(6):101541. [11] 李梓萌,王清,温言,等. 幽门螺杆菌感染与2型糖尿病患者血糖及胰岛素抵抗的关系[J]. 中国实验诊断学, 2022, 26(5):717-720. [12] 刘浚沅,贺永梅,侯晓琳,等. 健康体检人群不同分型幽门螺杆菌感染与代谢综合征的关系[J]. 中国综合临床, 2021, 37(6):555-559. [13] 钟玉福, 林明强, 冯奇桃, 等. 肝硬化并发上消化道出血的危险因素及其Hp感染基因型与Foxp3和RORγt基因表达水平[J]. 中华医院感染学杂志, 2023, 33(12):1814-1818. [14] Liu W, Wang Q, Yeerlan J, et al. Global research trends and hotspots for leukocyte cell-derived chemotaxin-2 from the past to 2023:a combined bibliometric review[J]. Front Immunol, 2024, 15:1413466. [15] Chen X, Peng R, Peng D, et al. Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways:a transcriptomic study[J]. J Transl Med, 2024, 22(1):701. [16] Paine-Cabrera D, Harvey L K, Robarts D R,et al. Leukocyte cell-derived chemotaxin 2 correlates with pediatric non-alcoholic fatty liver disease[J]. Clin Transl Sci, 2023, 16(12):2719-2728. [17] Zhao C F. Association between Helicobacter pylori infection and metabolic dysfunction-associated steatohepatitis:from an analysis of a population-based study[J]. World J Hepatol, 2025, 17(2):102734. [18] Tanida R, Goto H, Takayama H, et al. LECT2 deletion exacerbates liver steatosis and macrophage infiltration in a male mouse model of LPS-mediated NASH[J]. Endocrinology, 2024, 165(7):bqae059. [19] Chen X, Peng R, Peng D, et al. An update:is there a relationship between H. pylori infection and nonalcoholic fatty liver disease? Why is this subject of interest?[J]. Front Cell Infect Microbiol, 2023, 13:1282956. [20] 雷佩茹,李迎杰,李静. 非酒精性脂肪性肝病合并2型糖尿病患者同型半胱氨酸水平和中性粒细胞与淋巴细胞比值的临床意义[J]. 临床肝胆病杂志, 2021, 37(10):2352-2356. |